Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2008

Open Access 01-12-2008 | Research

Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea

Authors: Freya JI Fowkes, Pascal Michon, Lynn Pilling, Ruth M Ripley, Livingstone Tavul, Heather J Imrie, Caira M Woods, Charles S Mgone, Adrian JF Luty, Karen P Day

Published in: Malaria Journal | Issue 1/2008

Login to get access

Abstract

Background

The protection afforded by human erythrocyte polymorphisms against the malaria parasite, Plasmodium falciparum, has been proposed to be due to reduced ability of the parasite to invade or develop in erythrocytes. If this were the case, variable levels of parasitaemia and rates of seroconversion to infected-erythrocyte variant surface antigens (VSA) should be seen in different host genotypes.

Methods

To test this hypothesis, P. falciparum parasitaemia and anti-VSA antibody levels were measured in a cohort of 555 asymptomatic children from an area of intense malaria transmission in Papua New Guinea. Linear mixed models were used to investigate the effect of α+-thalassaemia, complement receptor-1 and south-east Asian ovalocytosis, as well as glucose-6-phosphate dehydrogenase deficiency and ABO blood group on parasitaemia and age-specific seroconversion to VSA.

Results

No host polymorphism showed a significant association with both parasite prevalence/density and age-specific seroconversion to VSA.

Conclusion

Host erythrocyte polymorphisms commonly found in Papua New Guinea do not effect exposure to blood stage P. falciparum infection. This contrasts with data for sickle cell trait and highlights that the above-mentioned polymorphisms may confer protection against malaria via distinct mechanisms.
Appendix
Available only for authorised users
Literature
1.
Allen SJ, O'Donnell A, Alexander ND, Alpers MP, Peto TE, Clegg JB, Weatherall DJ: alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci USA. 1997, 94: 14736-14741. 10.1073/pnas.94.26.14736.PubMedCentralCrossRefPubMed
2.
Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah RN, Dietz E, Anemana SD, Bienzle U: alpha+-Thalassemia protects African children from severe malaria. Blood. 2004, 104: 2003-2006. 10.1182/blood-2003-11-4090.CrossRefPubMed
3.
Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK, Newton CR, Maitland K: Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood. 2005, 106: 368-371. 10.1182/blood-2005-01-0313.CrossRef
4.
Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, Mwacharo JK, Weatherall DJ, Snow RW, Marsh K, Williams TN: The effect of alpha(+)-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med. 2006, 3: e158-10.1371/journal.pmed.0030158.PubMedCentralCrossRefPubMed
5.
Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, Rowe JA: A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA. 2004, 101: 272-277. 10.1073/pnas.0305306101.PubMedCentralCrossRefPubMed
6.
Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, Newbold CI, Greenwood BM, Marsh K, Hill AVS: Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995, 376: 246-249. 10.1038/376246a0.CrossRefPubMed
7.
Allen SJ, O'Donnell A, Alexander ND, Mgone CS, Peto TE, Clegg JB, Alpers MP, Weatherall DJ: Prevention of cerebral malaria in children in Papua New Guinea by southeast Asian ovalocytosis band 3. Am J Trop Med Hyg. 1999, 60: 1056-1060.PubMed
8.
Genton B, al-Yaman F, Mgone CS, Alexander N, Paniu MM, Alpers MP, Mokela D: Ovalocytosis and cerebral malaria [letter]. Nature. 1995, 378: 564-565. 10.1038/378564a0.CrossRefPubMed
9.
Fischer PR, Boone P: Short report: severe malaria associated with blood group. Am J Trop Med Hyg. 1998, 58: 122-123.PubMed
10.
Lell B, May J, Schmidt-Ott RJ, Lehman LG, Luckner D, Greve B, Matousek P, Schmid D, Herbich K, Mockenhaupt FP, Meyer CG, Bienzle U, Kremsner PG: The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis. 1999, 28: 794-799. 10.1086/515193.CrossRefPubMed
11.
Williams TN, Mwangi TW, Wambua S, Peto TE, Weatherall DJ, Gupta S, Recker M, Penman BS, Uyoga S, Macharia A, Mwacharo JK, Snow RW, Marsh K: Negative epistasis between the malaria-protective effects of alpha(+)-thalassemia and the sickle cell trait. Nat Genet. 2005, 37: 1253-1257. 10.1038/ng1660.PubMedCentralCrossRefPubMed
12.
Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA: X-Linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007, 4: e66-10.1371/journal.pmed.0040066.PubMedCentralCrossRefPubMed
13.
Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D: Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood. 2000, 96: 2358-2363.PubMed
14.
Mockenhaupt FP, Ehrhardt S, Cramer JP, Otchwemah RN, Anemana SD, Goltz K, Mylius F, Dietz E, Eggelte TA, Bienzle U: Hemoglobin C and resistance to severe malaria in Ghanaian children. J Infect Dis. 2004, 190: 1006-1009. 10.1086/422847.CrossRefPubMed
15.
Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, Rastrelli E, Olivieri A, Calissano C, Paganotti GM, D'Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M: Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature. 2001, 414: 305-308. 10.1038/35104556.CrossRefPubMed
16.
Hutagalung R, Wilairatana P, Looareesuwan S, Brittenham GM, Aikawa M, Gordeuk VR: Influence of hemoglobin E trait on the severity of Falciparum malaria. J Infect Dis. 1999, 179: 283-286. 10.1086/314561.CrossRefPubMed
17.
Chotivanich K, Udomsangpetch R, Pattanapanyasat K, Chierakul W, Simpson J, Looareesuwan S, White N: Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood. 2002, 100: 1172-1176.PubMed
18.
Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, Nahlen BL, Lal AA, Udhayakumar V: Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet. 2002, 359: 1311-1312. 10.1016/S0140-6736(02)08273-9.CrossRefPubMed
19.
Williams TN, Mwangi TW, Roberts DJ, Alexander ND, Weatherall DJ, Wambua S, Kortok M, Snow RW, Marsh K: An Immune Basis for Malaria Protection by the Sickle Cell Trait. PLoS Med. 2005, 2: e128-10.1371/journal.pmed.0020128.PubMedCentralCrossRefPubMed
20.
Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, Marsh K: Sickle Cell Trait and the Risk of Plasmodium falciparum Malaria and Other Childhood Diseases. J Infect Dis. 2005, 192: 178-186. 10.1086/430744.PubMedCentralCrossRefPubMed
21.
Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Kone A, Diallo DA, Raza A, Kai O, Marsh K, Plowe CV, Doumbo OK, Moulds JM: Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci USA. 2007, 104: 17471-17476. 10.1073/pnas.0705390104.PubMedCentralCrossRefPubMed
22.
May J, Evans JA, Timmann C, Ehmen C, Busch W, Thye T, Agbenyega T, Horstmann RD: Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007, 297: 2220-2226. 10.1001/jama.297.20.2220.CrossRefPubMed
23.
Williams TN: Red blood cell defects and malaria. Mol Biochem Parasitol. 2006, 149: 121-127. 10.1016/j.molbiopara.2006.05.007.CrossRefPubMed
24.
Ayi K, Turrini F, Piga A, Arese P: Enhanced phagocytosis of ring-parasitized mutant erythrocytes. A common mechanism that may explain protection against falciparum-malaria in sickle-trait and beta-thalassemia-trait. Blood. 2004, 104: 3364-3371. 10.1182/blood-2003-11-3820.CrossRefPubMed
25.
Giribaldi G, Ulliers D, Mannu F, Arese P, Turrini F: Growth of Plasmodium falciparum induces stage-dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes. Br J Haematol. 2001, 113: 492-499. 10.1046/j.1365-2141.2001.02707.x.CrossRefPubMed
26.
Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P: Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 1998, 92: 2527-2534.PubMed
27.
Destro-Bisol G, D'Aloja E, Spedini G, Scatena R, Giardina B, Pascali V: Brief communication: Resistance to Falciparum malaria in alpha-thalassemia, oxidative stress, and hemoglobin oxidation. Am J Phys Anthropol. 1999, 109: 269-273. 10.1002/(SICI)1096-8644(199906)109:2<269::AID-AJPA11>3.0.CO;2-#.CrossRef
28.
Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G: Protection by alpha-thalassaemia against Plasmodium falciparum malaria: modified surface antigen expression rather than impaired growth or cytoadherence. Immunol Lett. 1991, 30: 233-240. 10.1016/0165-2478(91)90031-5.CrossRefPubMed
29.
Stoute JA: Complement-regulatory proteins in severe malaria: too little or too much of a good thing?. Trends Parasitol. 2005, 21: 218-223. 10.1016/j.pt.2005.03.004.CrossRefPubMed
30.
Rowe A, Obeiro J, Newbold CI, Marsh K: Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun. 1995, 63: 2323-2326.PubMedCentralPubMed
31.
Udomsangpetch R, Todd J, Carlson J, Greenwood BM: The effects of hemoglobin genotype and ABO blood group on the formation of rosettes by Plasmodium falciparum-infected red blood cells. Am J Trop Med Hyg. 1993, 48: 149-153.PubMed
32.
Carlson J, Nash GB, Gabutti V, al-Yaman F, Wahlgren M: Natural protection against severe Plasmodium falciparum malaria due to impaired rosette formation. Blood. 1994, 84: 3909-3914.PubMed
33.
34.
Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM: Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991, 352: 595-600. 10.1038/352595a0.CrossRef
35.
Allen SJ, Rowe P, Allsopp CE, Riley EM, Jakobsen PH, Hill AV, Greenwood BM: A prospective study of the influence of alpha thalassaemia on morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in Gambian children. Trans R Soc Trop Med Hyg. 1993, 87: 282-285. 10.1016/0035-9203(93)90129-E.CrossRefPubMed
36.
Aluoch JR: Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Trop Med Int Health. 1997, 2: 568-571. 10.1046/j.1365-3156.1997.d01-322.x.CrossRefPubMed
37.
Le Hesran JY, Personne I, Personne P, Fievet N, Dubois B, Beyeme M, Boudin C, Cot M, Deloron P: Longitudinal study of Plasmodium falciparum infection and immune responses in infants with or without the sickle cell trait. Int J Epidemiol. 1999, 28: 793-798. 10.1093/ije/28.4.793.CrossRefPubMed
38.
Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM: Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg. 1989, 83: 293-303. 10.1016/0035-9203(89)90478-1.CrossRef
39.
Sokhna CS, Rogier C, Dieye A, Trape JF: Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune population exposed to intense perennial transmission. Am J Trop Med Hyg. 2000, 62: 266-270.PubMed
40.
Ackerman H, Usen S, Jallow M, Sisay-Joof F, Pinder M, Kwiatkowski DP: A comparison of case-control and family-based association methods: the example of sickle-cell and malaria. Ann Hum Genet. 2005, 69: 559-565. 10.1111/j.1529-8817.2005.00180.x.CrossRefPubMed
41.
Missinou MA, Lell B, Kremsner PG: Uncommon asymptomatic Plasmodium falciparum infections in Gabonese children. Clin Infect Dis. 2003, 36: 1198-1202. 10.1086/374555.CrossRefPubMed
42.
Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED: Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol. 1979, 73: 161-172.PubMed
43.
Gendrel D, Kombila M, Nardou M, Gendrel C, Djouba F, Richard-Lenoble D: Protection against Plasmodium falciparum infection in children with hemoglobin S. Pediatr Infect Dis J. 1991, 10: 620-621. 10.1097/00006454-199108000-00013.CrossRefPubMed
44.
Allen SJ, Bennett S, Riley EM, Rowe PA, Jakobsen PH, O'Donnell A, Greenwood BM: Morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in children with sickle cell trait in The Gambia. Trans R Soc Trop Med Hyg. 1992, 86: 494-498. 10.1016/0035-9203(92)90083-O.CrossRefPubMed
45.
Oppenheimer SJ, Higgs DR, Weatherall DJ, Barker J, Spark RA: Alpha thalassaemia in Papua New Guinea. Lancet. 1984, 1: 424-426. 10.1016/S0140-6736(84)91754-9.CrossRefPubMed
46.
Enevold A, Alifrangis M, Sanchez JJ, Carneiro I, Roper C, Borsting C, Lusingu J, Vestergaard LS, Lemnge MM, Morling N, riley E, Drakely CJ: Associations between alpha+-thalassemia and Plasmodium falciparum malarial infection in northeastern Tanzania. Journal of Infectious Diseases. 2007, 196: 451-459. 10.1086/519390.CrossRefPubMed
47.
Cattani JA, Gibson FD, Alpers MP, Crane GG: Hereditary ovalocytosis and reduced susceptibility to malaria in Papua New Guinea. Trans R Soc Trop Med Hyg. 1987, 81 (5): 705-9. 10.1016/0035-9203(87)90001-0.CrossRefPubMed
48.
Foo LC, Rekhraj V, Chiang GL, Mak JW: Ovalocytosis protects against severe malaria parasitemia in the Malayan aborigines. Am J Trop Med Hyg. 1992, 47: 271-275.PubMed
49.
Domarle O, Migot-Nabias F, Mvoukani JL, Lu CY, Nabias R, Mayombo J, Tiga H, Deloron P: Factors influencing resistance to reinfection with Plasmodium falciparum. Am J Trop Med Hyg. 1999, 61: 926-931.PubMed
50.
Moyano M, Mendez F: [Erythrocyte defects and parasitemia density in patients with Plasmodium falciparum malaria in Buenaventura, Colombia]. Rev Panam Salud Publica. 2005, 18: 25-32. 10.1590/S1020-49892005000600005.CrossRef
51.
Parikh S, Dorsey G, Rosenthal PJ: Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg. 2004, 71: 750-753.PubMed
52.
Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL, Krishnamoorthy R: Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg. 2003, 68: 186-190.PubMed
53.
Oo M, Tin S, Marlar T, O'Sullivan WJ: Genetic red cell disorders and severity of falciparum malaria in Myanmar. Bull World Health Organ. 1995, 73: 659-665.PubMedCentralPubMed
54.
Imrie H, Fowkes FJ, Michon P, Tavul L, Hume JC, Piper KP, Reeder JC, Day KP: Haptoglobin levels are associated with haptoglobin genotype and {alpha}+-thalassemia in a malaria-endemic area. Am J Trop Med Hyg. 2006, 74: 965-971.PubMed
55.
Montoya F, Restrepo M, Montoya AE, Rojas W: Blood groups and malaria. Rev Inst Med Trop Sao Paulo. 1994, 36: 33-38.CrossRefPubMed
56.
Shimizu H, Tamam M, Soemantri A, Ishida T: Glucose-6-phosphate dehydrogenase deficiency and Southeast Asian ovalocytosis in asymptomatic Plasmodium carriers in Sumba island, Indonesia. J Hum Genet. 2005, 50: 420-424. 10.1007/s10038-005-0271-7.CrossRefPubMed
57.
Patel SS, King CL, Mgone CS, Kazura JW, Zimmerman PA: Glycophorin C (Gerbich antigen blood group) and band 3 polymorphisms in two malaria holoendemic regions of Papua New Guinea. Am J Hematol. 2004, 75: 1-5. 10.1002/ajh.10448.PubMedCentralCrossRefPubMed
58.
Facer CA, Brown J: ABO blood groups and falciparum malaria. Trans R Soc Trop Med Hyg. 1979, 73: 599-600. 10.1016/0035-9203(79)90066-X.CrossRefPubMed
59.
Martin SK, Miller LH, Hicks CU, David-West A, Ugbode C, Deane M: Frequency of blood group antigens in Nigerian children with falciparum malaria. Trans R Soc Trop Med Hyg. 1979, 73: 216-218. 10.1016/0035-9203(79)90217-7.CrossRefPubMed
60.
Mockenhaupt FP, Falusi AG, May J, Ademowo OG, Olumese PE, Meyer CG, Bienzle U: The contribution of alpha+-thalassaemia to anaemia in a Nigerian population exposed to intense malaria transmission. Trop Med Int Health. 1999, 4: 302-307. 10.1046/j.1365-3156.1999.00386.x.CrossRefPubMed
61.
Oppenheimer SJ, Hill AV, Gibson FD, Macfarlane SB, Moody JB, Pringle J: The interaction of alpha thalassaemia with malaria. Trans R Soc Trop Med Hyg. 1987, 81: 322-326. 10.1016/0035-9203(87)90253-7.CrossRefPubMed
62.
Williams TN, Maitland K, Bennett S, Ganczakowski M, Peto TE, Newbold CI, Bowden DK, Weatherall DJ, Clegg JB: High incidence of malaria in alpha-thalassaemic children. Nature. 1996, 383: 522-525. 10.1038/383522a0.CrossRefPubMed
63.
Bienzle U, Guggenmoos-Holzmann I, Luzzatto L: Plasmodium falciparum malaria and human red cells. I. A genetic and clinical study in children. Int J Epidemiol. 1981, 10: 9-15. 10.1093/ije/10.1.9.CrossRefPubMed
64.
O'Donnell A, Allen SJ, Mgone CS, Martinson JJ, Clegg JB, Weatherall DJ: Red cell morphology and malaria anaemia in children with Southeast-Asian ovalocytosis band 3 in Papua New Guinea. Br J Haematol. 1998, 101: 407-412. 10.1046/j.1365-2141.1998.00742.x.CrossRefPubMed
65.
Fowkes FJ, Imrie H, Migot-Nabias F, Michon P, Justice A, Deloron P, Luty AJ, Day KP: Association of haptoglobin levels with age, parasite density, and haptoglobin genotype in a malaria-endemic area of Gabon. Am J Trop Med Hyg. 2006, 74: 26-30.PubMed
66.
Snow RW, Marsh K: New insights into the epidemiology of malaria relevant for disease control. Br Med Bull. 1998, 54: 293-309.CrossRef
67.
Piper KP, Roberts DJ, Day KP: Plasmodium falciparum: analysis of the antibody specificity to the surface of the trophozoite-infected erythrocyte. Exp Parasitol. 1999, 91: 161-169. 10.1006/expr.1998.4368.CrossRefPubMed
68.
Askjaer N, Maxwell C, Chambo W, Staalsoe T, Nielsen M, Hviid L, Curtis C, Theander TG: Insecticide-treated bed nets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clin Diagn Lab Immunol. 2001, 8: 1289-1291. 10.1128/CDLI.8.6.1289-1291.2001.PubMedCentralPubMed
69.
Gupta S, Trenholme K, Anderson RM, Day KP: Antigenic diversity and the transmission dynamics of Plasmodium falciparum. Science. 1994, 263: 961-963. 10.1126/science.8310293.CrossRefPubMed
70.
Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Heywood PF, Alpers MP, Stevenson A, Clancy R: The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg. 1986, 35: 3-15.PubMed
71.
Jarolim P, Palek J, Amato D, Hassan K, Sapak P, Nurse GT, Rubin HL, Zhai S, Sahr KE, Liu SC: Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci USA. 1991, 88: 11022-11026. 10.1073/pnas.88.24.11022.PubMedCentralCrossRefPubMed
72.
Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N: Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci USA. 1992, 89: 5847-5851. 10.1073/pnas.89.13.5847.PubMedCentralCrossRefPubMed
73.
Cox MJ, Kum DE, Tavul L, Narara A, Raiko A, Baisor M, Alpers MP, Medley GF, Day KP: Dynamics of malaria parasitaemia associated with febrile illness in children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med Hyg. 1994, 88: 191-197. 10.1016/0035-9203(94)90292-5.CrossRefPubMed
74.
Trager W, Jensen JB: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.CrossRefPubMed
75.
Day KP, Karamalis F, Thompson J, Barnes DA, Peterson C, Brown H, Brown GV, Kemp DJ: Genes necessary for expression of a virulence determinant and for transmission of Plasmodium falciparum are located on a 0.3-megabase region of chromosome 9. Proc Natl Acad Sci USA. 1993, 90: 8292-8296. 10.1073/pnas.90.17.8292.PubMedCentralCrossRefPubMed
76.
Pasvol G, Wilson RJ, Smalley ME, Brown J: Separation of viable schizont-infected red cells of Plasmodium falciparum from human blood. Ann Trop Med Parasitol. 1978, 72: 87-88.PubMed
77.
Vulliamy T, Luzzatto L, Hirono A, Beutler E: Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis. 1997, 23: 302-313. 10.1006/bcmd.1997.0147.CrossRef
78.
R Development Core Team: R: A Language and Environment for Statistical Computing. 2005, Vienna, Austria: R Foundation for Statistical Computing
79.
Kinyanjui SM, Mwangi T, Bull PC, Newbold CI, Marsh K: Protection against clinical malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte variant surface antigens requires interaction with asymptomatic infections. J Infect Dis. 2004, 190: 1527-1533. 10.1086/424675.CrossRef
80.
Weatherall DJ, Clegg JB: The Thalassaemia Syndromes. 2001, Oxford: Blackwell Science, 4CrossRef
81.
Rowe JA, Obiero J, Marsh K, Raza A: Short report: Positive correlation between rosetting and parasitemia in Plasmodium falciparum clinical isolates. Am J Trop Med Hyg. 2002, 66: 458-460.PubMed
82.
Cabrera G, Cot M, Migot-Nabias F, Kremsner PG, Deloron P, Luty AJ: The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis. 2005, 191: 1631-1638. 10.1086/429832.CrossRefPubMed
83.
Verra F, Simpore J, Warimwe GM, Tetteh KK, Howard T, Osier FH, Bancone G, Avellino P, Blot I, Fegan G: Haemoglobin C and S Role in Acquired Immunity against Plasmodium falciparum Malaria. PLoS ONE. 2007, 2: e978-10.1371/journal.pone.0000978.PubMedCentralCrossRefPubMed
Metadata
Title
Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea
Authors
Freya JI Fowkes
Pascal Michon
Lynn Pilling
Ruth M Ripley
Livingstone Tavul
Heather J Imrie
Caira M Woods
Charles S Mgone
Adrian JF Luty
Karen P Day
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2008
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-7-1

Other articles of this Issue 1/2008

Malaria Journal 1/2008 Go to the issue

Research

Determinants of the accuracy of rapid diagnostic tests in malaria case management: evidence from low and moderate transmission settings in the East African highlands

Research

Malaria incidence in Limpopo Province, South Africa, 1998–2007

Review

Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy

Research

Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania

Methodology

Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films

Research

The acceptability of intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in southern Tanzania
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits